Filing Flows › 8-K events › GoodRx Holdings
GoodRx Holdings: non-reliance on previously issued financial statements (restatement)
Form 8-K filed Nov 2, 2026 · items 4.02
What the filing says
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim On October 27, 2026, the Audit and Risk Committee of the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the
Read the filing on SEC EDGAR →
What usually followsAcross 173 8-Ks reporting Item 4.02 (restatement: financials not to be relied on) in our universe, the stock's median move the next session was −0.2% (typical size ±2.2%, up 42% of the time); over the following 21 sessions, 0.0%. Every item ranked →
What this kind of filing means
Item 4.02 — Non-reliance on previously issued financial statements (restatement). Non-reliance means earlier financial statements should no longer be relied on: a restatement is coming.
GoodRx Holdings at a glance
GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%. The chart follows the revenue to costs, profit and cash.
GoodRx Holdings: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent restatements
- Sidus Space Nov 6, 2026
- Driven Brands Holdings Nov 3, 2026
- Polomar Health Services Nov 3, 2026
- Panamera Holdings Oct 26, 2026
- Datavault AI Oct 26, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.